雙歧桿菌活菌膠囊聯合柳氮磺吡啶腸溶片治療潰瘍性結腸炎的效果及對患者血清炎癥因子水平的影響

李水康 李振飛

【摘要】 目的：探討柳氮磺吡啶腸溶片聯合雙歧桿菌活菌膠囊治療潰瘍性結腸炎的臨床效果及對患者血清炎癥因子水平的影響。方法：選取本院消化內科2016年9月-2018年5月收治的82例潰瘍性結腸炎患者，根據入院先后順序分為試驗組和對照組，各41例。對照組給予柳氮磺吡啶腸溶片治療，試驗組在對照組的基礎上給予雙歧桿菌活菌膠囊治療。連續治療8周后，比較兩組治療效果、腸道菌群、血清炎癥因子水平及T淋巴細胞亞群情況。結果：試驗組治療總有效率為92.68%明顯高于對照組的75.61%（P<0.05）。治療后，試驗組雙歧桿菌、腸球菌及乳酸菌數量均明顯高于對照組（P<0.05），試驗組腫瘤壞死因子-α（TNF-α）、IL-6、IL-8、C反應蛋白（CRP）及降鈣素原（PCT）均明顯低于對照組（P<0.05），試驗組CD3+、CD4+及CD4+/CD8+均低于對照組，而CD8+高于對照組（P<0.05）。結論：雙歧桿菌活菌膠囊聯合柳氮磺吡啶腸溶片治療潰瘍性結腸炎能有效提高治療效果，降低炎癥反應，改善免疫功能。

【關鍵詞】 雙歧桿菌活菌膠囊 柳氮磺吡啶腸溶片 潰瘍性結腸炎 血清炎癥因子

Effect of Live Bifidobacterium Capsules Combined with Sulfasalazine Enteric-coated Tablets on Ulcerative Colitis and Its Effect on Serum Inflammatory Factors/LI Shuikang， LI Zhenfei. //Medical Innovation of China， 2020， 17（04）： 0-023

[Abstract] Objective： To investigate the clinical effect of Sulfasalazine Enteric-coated Tablets combined with Live Bifidobacterium Capsules in the treatment of ulcerative colitis and its effect on serum inflammatory factors. Method： A total of 82 patients with ulcerative colitis admitted to the department of gastroenterology in our hospital from September 2016 to May 2018 were selected， and they were divided into experimental group and control group according to the order of admission， 41 cases in each group. The control group was treated with Sulfasalazine Enteric-coated Tablets， and the experimental group was treated with Live Bifidobacterium Capsules on the basis of the control group. After 8 weeks of continuous treatment， treatment effect， intestinal flora， serum inflammatory factors and T lymphocyte subsets of the two groups were compared. Result： The total effective rate in the experimental group was 92.68% significantly higher than 75.61% in the control group （P<0.05）. After treatment， the number of Bifidobacteria， Enterococcus and Lactobacillus in the experimental group were significantly higher than those in the control group （P<0.05）. Tumor necrosis factor-α （TNF-α）， IL-6， IL-8， C-reactive protein （CRP） and procalcitonin （PCT） in the experimental group were significantly lower than those in the control group （P<0.05）. After treatment， CD3+， CD4+ and CD4+/CD8+ in the experimental group were lower than those in the control group， while CD8+ was higher than that in the control group （P<0.05）. Conclusion： Live Bifidobacterium Capsules combined with Sulfasalazine Enteric-coated Tablets can effectively improve the treatment effect of ulcerative colitis， reduce inflammation and improve immune function.

[Key words] Live Bifidobacterium Capsules Sulfasalazine Enteric-coated Tablets Ulcerative colitis Serum inflammatory factor

First-authors address： Wuchuan Peoples Hospital， Wuchuan 524500， China

doi：10.3969/j.issn.1674-4985.2020.04.005

潰瘍性結腸炎是發生于結腸和直腸的慢性非特異性炎癥性疾病，病變局限于黏膜和黏膜下層，多發于乙狀結腸和直腸，偶可延伸至降結腸或整個結腸[1-2]。潰瘍性結腸炎以腹瀉為主要臨床癥狀，排出帶有血、膿和黏液糞便，常伴陣發性腸痙攣性疼痛，并里急后重[3-4]。多數患者起病緩慢，病情漫長，給患者帶來諸多不便。目前臨床上治療該病主要以柳氮磺吡啶治療為主，其療效確切，但治療后易復發、副作用大[5-6]。雙歧桿菌作為存在于人體消化道的正常菌群之一，對人體健康具有生物屏障、營養、調節免疫功能等作用[7]。潰瘍性結腸炎患者多存在腸道菌群比例失衡，加入外源性益生菌雙歧桿菌有望改善患者病情。本研究就柳氮磺吡啶腸溶片聯合雙歧桿菌活菌膠囊治療潰瘍性結腸炎的臨床效果及對患者血清炎癥因子水平的影響進行分析，現報道如下。……